- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on Ipamorelin
Ipamorelin is a synthetic pentapeptide developed in the late 1990s by Danish pharmaceutical company Novo Nordisk — specifically engineered to solve the main problems of earlier growth hormone secretagogues like GHRP-6 and GHRP-2. The design goal was simple: keep the GH-releasing effect, strip out everything else. That makes Ipamorelin the cleanest peptide in the GHRP class.
Mechanism in plain English
Same receptor pathway as its cousins: Ipamorelin mimics ghrelin at the GHSR-1a receptor and triggers a pulse of growth hormone from the pituitary. The difference is what it doesn't do. Unlike GHRP-6 and GHRP-2, Ipamorelin is highly selective — it barely touches cortisol, prolactin, or aldosterone, and produces minimal hunger response. You get the GH pulse without the baggage.
What it's used for
People take it for the full GH-axis lineup: better sleep quality, faster recovery, gradual body composition improvement, skin quality, joint comfort. First effects (deeper sleep, recovery) usually appear within 2-3 weeks. Visual changes follow at 2-3 months. The effect is accumulative and subtle, not dramatic.
Upsides and downsides
Main upside — selectivity. Unlike older GHRPs, Ipamorelin doesn't raise cortisol or prolactin meaningfully, doesn't cause wolf-level hunger, and doesn't mess with water retention. It's the peptide that made "clean GH stimulation" a realistic category.
Main downside, if you can call it that — modesty of effect. This isn't a "big result in a month" compound; it's a slow, steady tool that rewards consistency over intensity.
Typical protocol
Protocols run 200-300 mcg subcutaneously 2-3 times per day (morning fasted, pre-workout, before bed), over 8-12 week cycles. Injecting on an empty stomach matters — food blunts the GH pulse. Almost always stacked with a GHRH analog like CJC-1295 / Mod GRF 1-29 for synergistic effect.
Who should skip it
- Anyone with active cancer.
- Anyone with uncontrolled diabetes.
- Anyone with diabetic retinopathy.
Regulatory status
Banned by WADA year-round — detection methods exist and work. Not approved as a medication; sold as a research chemical.
By the mid-1990s, everyone working on growth hormone secretagogues had the same problem. GHRP-6 worked beautifully — it released GH from the pituitary, it was potent, it was oral-active. But it also cranked up cortisol, prolactin, and appetite. GHRP-2 was more potent but had the same side profile. Hexarelin was stronger still, with even more hormonal crossover and a tachyphylaxis problem on top of it.
Researchers at Novo Nordisk asked a specific chemistry question: could you strip the GHRP scaffold down to its absolute essentials and keep the GH-releasing power while losing the side effects? After systematic work on hundreds of candidate compounds, they isolated one in 1997 that did exactly that. They gave it the development code NNC 26-0161. The world came to know it as Ipamorelin — the first GHRP-class compound that released growth hormone without touching cortisol, prolactin, or aldosterone at even 200 times the effective dose [1].
Today it's the most widely used peptide in anti-aging, wellness, and performance medicine. And it's this way for a specific reason: it's the cleanest tool in its class.
Ipamorelin: what it is and how it works in a nutshell
Ipamorelin is a synthetic pentapeptide — just five amino acids (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) — making it the shortest functional GHRP ever developed. It was derived from GHRP-1 by the chemistry team at Novo Nordisk, who identified it within a series of compounds lacking the central Ala-Trp dipeptide [1].
The compound was originally investigated for postoperative ileus (delayed bowel recovery after abdominal surgery) by Helsinn Therapeutics, which took it through Phase II trials in 2014. The results were promising but didn't reach the primary composite endpoint [2]. Commercial development was discontinued, but the pharmacological profile was so clean that ipamorelin became the reference-standard GHRP in the research peptide world.
Not FDA-approved for any indication. Widely used off-label in anti-aging, performance, and regenerative medicine clinics, and it's probably the single most-prescribed peptide by physicians working in those spaces.
Ipamorelin mechanism of action: what it actually does in the body
Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor that ghrelin binds — on pituitary somatotroph cells. When the receptor activates, it triggers the phospholipase C → IP3 → calcium influx cascade that causes pituitary somatotrophs to release stored growth hormone [1].
The GH pulse pattern is rapid and physiological: peak plasma GH within 10-15 minutes of injection, return toward baseline within about 60-90 minutes. This pulsatile release pattern mimics how your body naturally secretes GH — which matters, because continuous GH elevation produces different and less favorable effects than pulsatile release.
The selectivity story — and why it matters.
The Raun et al. 1998 paper is the foundational document for ipamorelin. When the Novo Nordisk team tested their new compound in swine alongside GHRP-6, GHRP-2, and GHRH, something surprising happened. GHRP-6 and GHRP-2 both produced measurable increases in ACTH and cortisol at doses that stimulated GH. Ipamorelin didn't [1]. Even at doses 200-fold higher than the ED50 for GH release, ipamorelin produced no significant elevation of ACTH or cortisol — essentially matching GHRH for hormonal cleanness.
Practically, this means ipamorelin does not:
- Elevate cortisol (unlike GHRP-2, GHRP-6, hexarelin)
- Elevate prolactin meaningfully
- Stimulate aldosterone or other adrenal hormones
- Produce significant appetite stimulation (mild in some users, not near GHRP-6 levels)
This unique profile makes it the GHRP of choice for long-term use. Every other major GHRP has some hormonal crossover that accumulates as a concern over extended cycles. Ipamorelin largely doesn't.
The typical result downstream: elevated IGF-1 from amplified natural GH pulses, improved sleep architecture (deeper slow-wave sleep), enhanced recovery, gradual body composition improvements. All from a pentapeptide with a half-life of about 2 hours.
Who uses Ipamorelin and what for
- Adults over 30 seeking anti-aging benefits — the single largest user group. Natural GH production drops roughly 15% per decade after age 30, and ipamorelin (typically stacked with CJC-1295) is the most common peptide intervention for age-related GH decline.
- Athletes and lifters for recovery — not for raw muscle gain (that's not what this does), but for sleep quality, faster recovery between sessions, and gradual body composition improvements.
- People with sleep quality complaints — the natural nightly GH pulse happens during deep sleep. Ipamorelin reinforces this cycle, and improved sleep is often the first noticeable effect.
- Patients in men's and women's wellness clinics — probably the most commonly prescribed peptide in the integrative medicine space.
- Anyone who tried other GHRPs and had side effects — people who got hungry on GHRP-6, anxious on hexarelin, or felt the cortisol bump from GHRP-2 usually end up on ipamorelin.
- Researchers — ipamorelin's selectivity makes it the preferred pharmacological tool for studying the GH axis in isolation.
Realistic expectations over 8-12 weeks: noticeably deeper sleep (usually within 2-3 weeks), elevated IGF-1 on bloodwork, modest improvements in body composition over time (slight fat reduction, lean mass preservation), better recovery from training. Effects are cumulative and subtle rather than dramatic.
What WON'T happen: rapid muscle gain, dramatic fat loss, any acute effect you can feel after injection. Ipamorelin is a quiet workhorse — people expecting fireworks will be disappointed.
What Ipamorelin stacks with: popular combinations
Ipamorelin is usually the GHRP half of a GHRH + GHRP combination. The combinations:
- Ipamorelin + CJC-1295 (no DAC) — the gold standard peptide stack. CJC-1295 opens the GHRH receptor; ipamorelin opens the ghrelin receptor; both pituitary switches fire together for substantially greater GH release than either alone. This is what the Duo-Blend is.
- Ipamorelin + Sermorelin — milder GHRH partner for people starting conservatively.
- Ipamorelin + BPC-157 — common recovery stack. The GHS supports general healing environment; BPC-157 handles direct tissue repair.
- Ipamorelin + Tesamorelin — occasionally used in clinical settings for visceral fat targeting.
Generally not combined with: other GHRPs (GHRP-2, GHRP-6, hexarelin) — they compete for the same receptor.
Ipamorelin side effects and risks
Ipamorelin has probably the cleanest side effect profile of any peptide covered on this blog. In the Raun 1998 study, no adverse effects were observed with ipamorelin at any dose tested [1]. Decades of subsequent clinical and off-label use have confirmed this profile.
What occasionally shows up in practice:
- Mild flushing or warmth — brief, within minutes of injection, harmless
- Mild hunger increase — much less than GHRP-6 or GHRP-2, but present in some users
- Injection site reactions — small bumps, redness, transient
- Light head sensation — occasional, usually first few doses
- Water retention — mild, typically first 1-2 weeks
Also occasionally reported: slight fatigue shifts, vivid dreams (from deeper sleep), minor headache.
Who should be cautious or avoid:
- Anyone with active or recent history of cancer (GH/IGF-1 elevation is a theoretical concern)
- Diabetics with poor glucose control
- Pregnant or breastfeeding women
- Anyone under 25 without medical necessity
- Competitive athletes — Ipamorelin is on the WADA Prohibited List (S2) [3]
How to use and store Ipamorelin
Subcutaneous injection only. Oral bioavailability is essentially zero.
Typical protocols:
- Dose: 100-300 mcg per injection
- Frequency: 1-3 times daily
- Cycle: 8-12 weeks, followed by a break of at least 4 weeks (some clinicians use ipamorelin continuously for anti-aging purposes given its clean profile)
- Timing: on an empty stomach, at least 60-90 minutes after eating. Insulin and high blood glucose blunt GH release.
- Best injection windows: 30-60 minutes before bed (aligns with natural GH surge), post-workout, morning fasted
Multiple daily injections make sense because of ipamorelin's short half-life. A single daily shot captures only one GH pulse. Spreading 2-3 injections across the day captures natural release windows for cumulatively better results.
Storage: lyophilized form in freezer. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 30 days. Don't freeze the reconstituted solution.
Labs and monitoring during an Ipamorelin cycle
Before: IGF-1, fasting glucose, HbA1c, basic metabolic panel. Optional: fasting insulin.
During (week 4-6): IGF-1 and fasting glucose. IGF-1 should show measurable elevation — if it hasn't moved at all, check timing (was injection too close to meals?), product quality, or dose.
After: repeat IGF-1 and glucose 2-4 weeks post-cycle to confirm normalization.
Target: IGF-1 in the upper normal range for your age, not pushed above reference range.
Ipamorelin vs alternatives: what's different
- GHRP-2 — stronger GH release than ipamorelin, but raises cortisol and prolactin modestly. Better for short-term peak performance, worse for long-term wellness use.
- GHRP-6 — comparable GH release, dramatically stronger appetite effect. Preferred for people trying to gain weight or recover from wasting; avoided by most others.
- Hexarelin — most potent GHRP, but rapid tachyphylaxis and strongest cortisol/prolactin elevation. Specialist short-cycle tool, not a daily driver.
- MK-677 (Ibutamoren) — oral ghrelin mimetic with 24-hour half-life. Massive convenience advantage (pill form), but significantly stronger appetite effect and different insulin profile than ipamorelin.
- Tesamorelin — a GHRH analog, not a GHRP. Different mechanism entirely. FDA-approved for HIV lipodystrophy.
Ipamorelin's distinguishing feature: the cleanest GHRP ever designed. Not the strongest, not the longest-acting — but the most selective. For long-term wellness use, this selectivity is worth more than raw potency.
Myths about Ipamorelin
- "More injections means more GH means better results." Past a certain ceiling, no. The pituitary has finite stored GH to release in any given pulse. Hitting it 4-5 times daily at full doses produces diminishing returns — more total peptide exposure, not proportionally more GH release. Two to three daily injections at reasonable doses captures most of the benefit.
- "Ipamorelin is a cleaner version of HGH." It's not HGH at all. HGH is the actual growth hormone, exogenously administered. Ipamorelin is a peptide that tells your pituitary to release your own GH in its natural pulsatile pattern. The two produce measurably different physiological effects, different cost profiles, and different long-term safety considerations. Conflating them leads to wrong expectations in both directions.
Sources
- Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/ — foundational characterization of ipamorelin by the original Novo Nordisk team. Documents the unique selectivity for GH without ACTH/cortisol/prolactin elevation at doses up to 200x ED50.
- Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. — Phase II clinical trial in 114 patients examining ipamorelin for postoperative GI recovery.
- World Anti-Doping Agency (WADA). Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. https://www.wada-ama.org — ipamorelin classification in competitive sport.
- Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412-1416. — human pharmacokinetic characterization of ipamorelin.
- Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149-S159. — modern review of GHS combination therapy rationale including ipamorelin.
- Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272. — bone formation effects in glucocorticoid-treated rats.
Ipamorelin Dosage Guide
Ipamorelin is a fifth-generation selective growth hormone secretagogue — a pentapeptide ghrelin receptor agonist engineered specifically for GH release without the cortisol, prolactin, or appetite elevations seen with GHRP-2, GHRP-6, and Hexarelin. This guide is aimed at users prioritizing a clean anabolic profile for body composition, recovery, sleep quality, and anti-aging, as well as those seeking a long-term sustainable GH peptide without receptor desensitization concerns. Dosing below combines the Raun et al. Phase I pharmacokinetic trials, the 2014 Phase II postoperative ileus clinical study (100–300 mcg range), and the widely-used clinical protocols built around the standard 200–300 mcg per injection.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | Once daily, SC, pre-bed fasted | First 2 weeks; assess response |
| Standard | 200 mcg | Twice daily (AM fasted + pre-bed), SC | Most common community protocol |
| Intermediate | 200 mcg | 3 times daily, SC | Captures morning, post-workout, and nocturnal GH windows |
| Aggressive | 300 mcg | 3 times daily, SC | Near receptor saturation; no benefit above this |
| Clinical reference | 100–300 mcg | Per injection, SC | 2014 ileus trial range |
Doses also shift depending on the specific goal. The same peptide used for nightly sleep support versus aggressive recomposition can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Sleep quality / anti-aging | 100–200 mcg | Once daily, SC, 30 min pre-bed | 8–12 weeks on / 2–4 weeks off |
| Fat loss / body recomposition | 200 mcg | Twice daily, SC fasted | 12 weeks on / 4 weeks off |
| Muscle gain / recovery | 200–300 mcg | 3 times daily, SC fasted | 12–16 weeks on / 4 weeks off |
| Post-injury tissue repair | 200 mcg | Twice daily, SC | 6–8 weeks |
| Stacked with CJC-1295 no DAC | 100–200 mcg each | Twice daily, same syringe SC | 8–12 weeks |
| Stacked with CJC-1295 DAC | 200 mcg Ipamorelin daily + 1–2 mg CJC DAC weekly | Daily Ipamorelin + weekly DAC | 8–16 weeks |
Inject on an empty stomach with at least 2 hours since your last meal, ideally 30 minutes before bed to stack with the natural nocturnal GH surge — elevated insulin from food blunts the GH pulse regardless of dose. Unlike GHRP-2 and Hexarelin, Ipamorelin does not show significant tachyphylaxis even with chronic dosing, so 12–16 week cycles are sustainable and receptor desensitization is minimal. Absolute contraindications include active cancer diagnosis, diabetic retinopathy, and pregnancy — do not stack Ipamorelin with GHRP-2, GHRP-6, or Hexarelin since all four compete for the same GHS-R1a receptor; pair it with a GHRH analog like CJC-1295 for synergistic effect.
Ipamorelin Storage Guide: How to Keep Your Research Peptide Stable and Effective
Ipamorelin ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its pentapeptide structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a frost-free freezer with temperature swings, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Ipamorelin is a synthetic pentapeptide — a chain of just five amino acids — that belongs to a class of compounds called growth hormone secretagogues. Developed by Novo Nordisk in the late 1990s, it was designed to selectively trigger the release of your body's own growth hormone without affecting other hormones like cortisol or prolactin. It is not FDA-approved for human use and is generally sold as a research chemical or prescribed off-label through compounding pharmacies and wellness clinics.
Ipamorelin mimics ghrelin, often called the "hunger hormone," by binding to growth hormone secretagogue receptors (GHS-R) in the pituitary gland and hypothalamus. This binding prompts the pituitary to release a natural pulse of growth hormone (GH), which in turn raises levels of insulin-like growth factor 1 (IGF-1) in the liver. Unlike synthetic HGH injections, ipamorelin works with your body's own hormonal rhythms, producing pulsatile GH release rather than a constant flood. Its effects on GH last roughly 2–3 hours per dose.
Users and clinicians report benefits including improved lean muscle mass, reduced body fat, better sleep quality, faster exercise recovery, improved skin and hair quality, and a general sense of increased energy. These effects stem from the downstream rise in GH and IGF-1. However, most supporting evidence comes from small studies, animal research, and clinical observation — large, long-term human trials are still lacking, so many of these claims should be viewed as promising but not definitively proven.
A common clinical dose is 200 to 300 micrograms per injection, administered subcutaneously one to three times per day. Because ipamorelin has a short half-life of about two hours, some protocols split the dose — one shot before bed to align with the natural overnight GH peak, and sometimes a second dose before training or upon waking. Typical cycles run 8 to 12 weeks followed by a break to prevent receptor desensitization. Doses should always be set by a qualified provider rather than copied from online forums.
Ipamorelin is considered one of the better-tolerated growth hormone peptides, but side effects can still occur. The most common are mild headaches, a temporary flushing or "head rush" sensation right after injection, fatigue, injection-site irritation, increased appetite, and occasional water retention. Less common effects include joint aches, numbness or tingling in the hands, and possible changes in insulin sensitivity. Serious adverse events are rare at proper subcutaneous doses, but intravenous injection has been associated with severe cardiovascular risk and should be avoided.
Most users notice subtle changes within the first two to four weeks, typically starting with better sleep quality and improved recovery from training. More visible changes — increased lean muscle, reduced body fat, improved skin tone — tend to emerge after 8 to 12 weeks of consistent use. Results depend heavily on diet, training, sleep, age, and baseline GH levels. Older adults with naturally declining GH often notice effects more dramatically than younger users who already have healthy hormone levels.
Ipamorelin is not FDA-approved as a standalone prescription drug and is not sold in regular pharmacies. In the United States it falls into a grey zone — it can be prescribed through compounding pharmacies (under 503A/503B regulations) and obtained legally with a prescription from a licensed clinician, or sold online as a research chemical labeled "not for human use." It is banned by WADA and most major sports organizations, so any competitive athlete using it risks a positive drug test and sanctions.
Synthetic HGH is the growth hormone itself — you inject a large external dose of the hormone directly. Ipamorelin is a signal that tells your own pituitary gland to release its own GH in natural pulses. This difference matters because HGH can shut down your natural production, cause significant side effects like insulin resistance and water retention, and produce supraphysiological hormone levels. Ipamorelin generally produces milder, more physiologic GH increases, which most clinicians consider safer for long-term use — though the trade-off is less dramatic results.
Yes, and this is actually one of the most popular peptide combinations in clinical and gym use. CJC-1295 mimics growth hormone-releasing hormone (GHRH), while ipamorelin mimics ghrelin — these are two separate signaling pathways that both stimulate GH release. Combining them produces a stronger and more sustained GH pulse than either peptide alone. The stack is typically dosed together once or twice daily, most often before bedtime to amplify the natural nighttime GH surge.
Ipamorelin generally supports fat loss rather than weight gain, because increased GH promotes lipolysis (fat breakdown) and lean muscle growth. That said, some users see the number on the scale stay the same or rise slightly — this is usually from added muscle mass or temporary water retention, not fat gain. A few users also report increased appetite because ipamorelin acts on ghrelin receptors, though this effect is typically milder than with similar peptides like MK-677.
